Halberd (Halberd) Asset Impairment Charge : $0.00 Mil (TTM As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Asset Impairment Charge?

Halberd's Asset Impairment Charge for the six months ended in Jul. 2023 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jul. 2023 was $0.00 Mil.

Halberd Asset Impairment Charge Historical Data

The historical data trend for Halberd's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Asset Impairment Charge Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

Asset Impairment Charge

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
Asset Impairment Charge	-	-	-

Halberd Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Asset Impairment Charge for the trailing twelve months (TTM) ended in Jul. 2023 was $0.00 Mil.

Halberd Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Halberd's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236